EODData

MEMBERSHIP REGISTER LOG IN

FRA, 2H51: Ocugen Inc

18 Aug 2026
LAST:

1.158

CHANGE:
 0.02		OPEN:
1.170		HIGH:
1.170		ASK:
0.000		VOLUME:
0
CHG(%):
1.36		PREV:
1.174		LOW:
1.158		BID:
0.000		 

CHART

RECENT END OF DAY PRICES

DateOpenHighLowCloseVolume
18 Aug 261.1701.1701.1581.158300
17 Aug 261.1741.1741.1741.1740
14 Aug 261.1521.1521.1521.1520
13 Aug 261.1941.2361.1941.2360
12 Aug 261.1701.1701.1701.1700
07 Aug 261.0781.0781.0781.07880
06 Aug 261.1361.1361.1361.1360
04 Aug 261.0761.0781.0761.078655
03 Aug 261.0681.1001.0681.1002.0K
31 Jul 261.1001.1001.0741.0740

PROFILE

Name:Ocugen Inc
About:Ocugen, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel gene and cell therapies, biologic, and vaccines that improve patients' health. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, currently under Phase 3 trials for the treatment of retinitis pigmentosa and Phase 1/2 trials for the treatment of leber congenital amaurosis; OCU410, a gene therapy under phase 1/2 for the treatment of dry age-related macular degeneration (AMD); and OCU410ST, a gene therapy under phase 1/2 for the treatment of Stargardt disease. It is involved in the development of OCU200, a novel fusion protein for the treatment of diabetic macular edema, diabetic retinopathy, and wet age-related macular degeneration; and NeoCart, an autologous chondrocyte-derived neocartilage, currently under Phase 3 studies indicated for the repair of knee cartilage injuries in adult. In addition, the company is developing OCU500, a COVID-19 vaccine; OCU510, a seasonal quadrivalent flu vaccine; and OCU520, a combination quadrivalent seasonal flu and COVID-19 vaccine. It has collaboration agreements with National Institute of Allergy and Infectious Diseases for early clinical studies for the OCU500 program; and a strategic partnership with CanSino Biologics Inc. for manufacturing its modifier gene therapy pipeline product candidates. The company was founded in 2013 and is headquartered in Malvern, Pennsylvania.
Sector:Healthcare
Industry:Biotechnology
Address:11 Great Valley Parkway, Malvern, PA, United States, 19355
Website:https://www.ocugen.com
ISIN:US67577C1053
LEI:549300JVNUI9CXWJLR09

API SERVICE  NEW

Have you tried our new API Service yet?

For more information, visit our API page.

You can get your ApiKey over HERE.

If you're ready to get going, then jump over to:
https://api.eoddata.com

SYMBOL HISTORY

   Add to Watchlist

DOWNLOAD DATA

Download stock quote history quickly and easily in a variety of formats to suit your needs.

  Download

FUNDAMENTALS

Trailing P/E:-5.46 
Forward P/E:5.02 
PEG Ratio:-0.27 
Price to Sales:95.23 
Price to Book:84.53 
Operating Margin:-11.64 
Return on Assets:-0.68 
Return on Equity:-6.60 
Revenue:3.91M 
Shares:312.3M 
Market Cap:361.65M 

TECHNICAL INDICATORS

MA5:1.181.7%
MA10:1.142.0%
MA20:1.132.6%
MA50:1.171.1%
MA100:1.3113.1%
MA200:1.3214.0%
STO9:50.63
STO14:51.85
RSI14:59.30
WPR14:-48.15
MTM14:0.07
ROC14:0.06 
ATR:0.04 
Week High:1.246.7%
Week Low:1.150.5%
Month High:1.246.7%
Month Low:1.0214.0%
Year High:2.35103.1%
Year Low:0.8536.2%

RECENT SPLITS

Date Ratio
01 Oct 20191-60
30 Sep 20191-60